CAS 1095207-05-8

Crenezumab

CAS : 1095207-05-8

Crenezumab (MABT 5102A) is a fully humanized anti-amyloid-beta antibody that binds to multiple forms of amyloid-beta (Aβ) for the study of Alzheimer's disease.

Degré de pureté : 97.5% (SDS-PAGE); 95.3% (SEC-HPLC) - 97.5% (SDS-PAGE); 95.3% (SEC-HPLC)

Couleur et forme : Liquid

Masse moléculaire : 143.32 kDa

Ref: TM-T77152

Crenezumab

CAS : 1095207-05-8

A fully humanized monoclonal antibody (from mouse) against human 1-42 β-amyloid (Aβ).

Ref: 3D-CLA1279